{"transactions":[{"id":676064,"issuer":{"id":4972,"kind":"organization","name":"ARDELYX, INC."},"owners":[{"id":19879,"kind":"person","name":"Bishop John E","position":1,"cik":"0001308911","reported_name":"Bishop John E","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2026-08-25T23:16:41.000Z","date":"2026-08-21","kind":"sale","planned":false,"acquired":false,"shares":2469,"price":3.8569,"value":9522.6861,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Pursuant to an automatic sell-to-cover imposed by the terms of the initial grant of the restricted stock units (\"RSUs\") awards, the shares were sold upon the vesting of the RSUs solely to cover applicable withholding taxes. The transaction was executed in multiple trades in prices ranging from $3.648 to $3.984, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote."}],"balance_after":317095,"source":{"system":"sec-edgar","filing":"0001308911-26-000007","document":"wk-form4_1787699798.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1437402/000130891126000007/wk-form4_1787699798.xml","form_type":"4"}},{"id":676063,"issuer":{"id":4972,"kind":"organization","name":"ARDELYX, INC."},"owners":[{"id":19879,"kind":"person","name":"Bishop John E","position":1,"cik":"0001308911","reported_name":"Bishop John E","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2026-08-25T23:16:41.000Z","date":"2026-08-21","kind":"sale","planned":false,"acquired":false,"shares":17281,"price":3.8569,"value":66651.0889,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Pursuant to an automatic sell-to-cover imposed by the terms of the initial grant of the restricted stock units (\"RSUs\") awards, the shares were sold upon the vesting of the RSUs solely to cover applicable withholding taxes. The transaction was executed in multiple trades in prices ranging from $3.648 to $3.984, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote."}],"balance_after":319564,"source":{"system":"sec-edgar","filing":"0001308911-26-000007","document":"wk-form4_1787699798.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1437402/000130891126000007/wk-form4_1787699798.xml","form_type":"4"}},{"id":765767,"issuer":{"id":4972,"kind":"organization","name":"ARDELYX, INC."},"owners":[{"id":19879,"kind":"person","name":"Bishop John E","position":1,"cik":"0001308911","reported_name":"Bishop John E","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2026-05-22T20:15:36.000Z","date":"2026-05-21","kind":"sale","planned":false,"acquired":false,"shares":2306,"price":6.2675,"value":14452.855,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Pursuant to an automatic sell-to-cover imposed by the terms of the initial grant of the restricted stock units (\"RSUs\") awards, the shares were sold upon the vesting of the RSUs solely to cover applicable withholding taxes."}],"balance_after":336845,"source":{"system":"sec-edgar","filing":"0001308911-26-000004","document":"wk-form4_1779480933.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1437402/000130891126000004/wk-form4_1779480933.xml","form_type":"4"}},{"id":887944,"issuer":{"id":4972,"kind":"organization","name":"ARDELYX, INC."},"owners":[{"id":19879,"kind":"person","name":"Bishop John E","position":1,"cik":"0001308911","reported_name":"Bishop John E","relationship":{"officer":true,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2026-02-24T01:54:33.000Z","date":"2026-02-20","kind":"sale","planned":false,"acquired":false,"shares":1,"price":5.7003,"value":5.7003,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Pursuant to an automatic sell-to-cover imposed by the terms of the initial grant of the restricted stock units (\"RSUs\") awards, the shares were sold upon the vesting of the RSUs solely to cover applicable withholding taxes."}],"balance_after":339151,"source":{"system":"sec-edgar","filing":"0001610717-26-000064","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1437402/000161071726000064/form4.xml","form_type":"4"}},{"id":887943,"issuer":{"id":4972,"kind":"organization","name":"ARDELYX, INC."},"owners":[{"id":19879,"kind":"person","name":"Bishop John E","position":1,"cik":"0001308911","reported_name":"Bishop John E","relationship":{"officer":true,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2026-02-24T01:54:33.000Z","date":"2026-02-20","kind":"sale","planned":false,"acquired":false,"shares":386,"price":5.7138,"value":2205.5268,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Pursuant to an automatic sell-to-cover imposed by the terms of the initial grant of the restricted stock units (\"RSUs\") awards, the shares were sold upon the vesting of the RSUs solely to cover applicable withholding taxes."}],"balance_after":339152,"source":{"system":"sec-edgar","filing":"0001610717-26-000064","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1437402/000161071726000064/form4.xml","form_type":"4"}},{"id":887942,"issuer":{"id":4972,"kind":"organization","name":"ARDELYX, INC."},"owners":[{"id":19879,"kind":"person","name":"Bishop John E","position":1,"cik":"0001308911","reported_name":"Bishop John E","relationship":{"officer":true,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2026-02-24T01:54:33.000Z","date":"2026-02-20","kind":"sale","planned":false,"acquired":false,"shares":2792,"price":5.865,"value":16375.08,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Pursuant to an automatic sell-to-cover imposed by the terms of the initial grant of the restricted stock units (\"RSUs\") awards, the shares were sold upon the vesting of the RSUs solely to cover applicable withholding taxes."}],"balance_after":339538,"source":{"system":"sec-edgar","filing":"0001610717-26-000064","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1437402/000161071726000064/form4.xml","form_type":"4"}},{"id":931123,"issuer":{"id":4972,"kind":"organization","name":"ARDELYX, INC."},"owners":[{"id":19879,"kind":"person","name":"Bishop John E","position":1,"cik":"0001308911","reported_name":"Bishop John E","relationship":{"officer":true,"officer_title":"See Remarks"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-01-26T21:22:09.000Z","date":"2026-01-23","kind":"grant","planned":false,"acquired":true,"shares":186500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The option becomes exercisable as it vests and the shares subject to the option vest in 48 successive, equal monthly installments on each monthly anniversary of January 23, 2026, subject to the Reporting Person's continued employment or service relationship with the Issuer on each such vesting date."}],"balance_after":186500,"derivative":{"exercise_price":7.77,"expiration_date":"2036-01-23","underlying":"Common Stock","underlying_shares":186500},"source":{"system":"sec-edgar","filing":"0001610717-26-000019","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1437402/000161071726000019/form4.xml","form_type":"4"}},{"id":931122,"issuer":{"id":4972,"kind":"organization","name":"ARDELYX, INC."},"owners":[{"id":19879,"kind":"person","name":"Bishop John E","position":1,"cik":"0001308911","reported_name":"Bishop John E","relationship":{"officer":true,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2026-01-26T21:22:09.000Z","date":"2026-01-23","kind":"grant","planned":false,"acquired":true,"shares":124330,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Restricted stock units (\"RSUs\"). The Reporting Person is entitled to receive one (1) shares of Common Stock for each one (1) RSU upon the vesting thereof."}],"balance_after":342330,"source":{"system":"sec-edgar","filing":"0001610717-26-000019","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1437402/000161071726000019/form4.xml","form_type":"4"}},{"id":1663744,"issuer":{"id":46837,"kind":"organization","name":"Lyra Therapeutics, Inc.","symbol":"LYRA"},"owners":[{"id":19879,"kind":"person","name":"Bishop John E","position":1,"cik":"0001308911","reported_name":"Bishop John E","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Technology Officer"}}],"security":"Stock Options","published_at":"2024-02-01T21:15:20.000Z","date":"2024-01-30","kind":"grant","planned":false,"acquired":true,"shares":200000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option vests and becomes exercisable in 48 equal monthly installments occurring on the completion of each successive month of the Reporting Person's service to the Issuer following January 30, 2024."}],"balance_after":200000,"derivative":{"exercise_price":4.58,"expiration_date":"2034-01-29","underlying":"Common Stock","underlying_shares":200000},"source":{"system":"sec-edgar","filing":"0000950170-24-009808","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1308911/000095017024009808/ownership.xml","form_type":"4"}},{"id":1986413,"issuer":{"id":46837,"kind":"organization","name":"Lyra Therapeutics, Inc.","symbol":"LYRA"},"owners":[{"id":19879,"kind":"person","name":"Bishop John E","position":1,"cik":"0001308911","reported_name":"Bishop John E","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Technology Officer"}}],"security":"Stock Option","published_at":"2023-02-28T21:10:19.000Z","date":"2023-02-27","kind":"grant","acquired":true,"shares":220000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option vests and becomes exercisable as to 25% of the underlying shares on February 27, 2024 and in 36 substantially equal monthly installments thereafter."}],"balance_after":220000,"derivative":{"exercise_price":2.31,"expiration_date":"2033-02-26","underlying":"Common Stock","underlying_shares":220000},"source":{"system":"sec-edgar","filing":"0000899243-23-006395","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1308911/000089924323006395/doc4.xml","form_type":"4"}},{"id":2136916,"issuer":{"id":123059,"kind":"organization","name":"Forma Therapeutics Holdings, Inc.","symbol":"FMTX"},"owners":[{"id":19879,"kind":"person","name":"Bishop John E","position":1,"cik":"0001308911","reported_name":"Bishop John E","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, Chief Technology Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2022-10-14T20:06:49.000Z","date":"2022-10-14","kind":"disposition_to_issuer","acquired":false,"shares":38930,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the \"Merger Agreement\"), dated as of August 31, 2022, by and among Forma Therapeutics Holdings, Inc. (the \"Issuer\"), Novo Nordisk A/S (the \"Parent\"), and NNUS New Dev, Inc., a wholly owned indirect subsidiary of Parent (\"Merger Sub\"), pursuant to which Merger Sub completed a cash tender offer for shares of common stock of the Issuer (each, a \"Share\") and thereafter merged with and into the Issuer (the \"Merger\"), effective as of October 14, 2022 (the \"Effective Time\"). At the Effective Time, each issued and outstanding Share was cancelled and converted into the right to receive $20.00 in cash (the \"Merger Consideration\"), subject to withholding of applicable taxes and without interest."},{"field":"kind","element":"transactionCoding","label":"F3","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each option (whether vested or unvested) that was outstanding and unexercised immediately prior to the Effective Time, was cancelled and converted into the right to receive, for each Share underlying such option, an amount in cash equal to the excess, if any, of the Merger Consideration over the exercise price per share of such option. Each option that was outstanding and unexercised immediately prior to the Effective Time which had a per share exercise price greater than or equal to the Merger Consideration was cancelled with no consideration payable."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each option (whether vested or unvested) that was outstanding and unexercised immediately prior to the Effective Time, was cancelled and converted into the right to receive, for each Share underlying such option, an amount in cash equal to the excess, if any, of the Merger Consideration over the exercise price per share of such option. Each option that was outstanding and unexercised immediately prior to the Effective Time which had a per share exercise price greater than or equal to the Merger Consideration was cancelled with no consideration payable."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each option (whether vested or unvested) that was outstanding and unexercised immediately prior to the Effective Time, was cancelled and converted into the right to receive, for each Share underlying such option, an amount in cash equal to the excess, if any, of the Merger Consideration over the exercise price per share of such option. Each option that was outstanding and unexercised immediately prior to the Effective Time which had a per share exercise price greater than or equal to the Merger Consideration was cancelled with no consideration payable."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each option (whether vested or unvested) that was outstanding and unexercised immediately prior to the Effective Time, was cancelled and converted into the right to receive, for each Share underlying such option, an amount in cash equal to the excess, if any, of the Merger Consideration over the exercise price per share of such option. Each option that was outstanding and unexercised immediately prior to the Effective Time which had a per share exercise price greater than or equal to the Merger Consideration was cancelled with no consideration payable."}],"balance_after":0,"derivative":{"exercise_price":9.86,"underlying":"Common Stock","underlying_shares":38930},"source":{"system":"sec-edgar","filing":"0000899243-22-033652","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1308911/000089924322033652/doc4.xml","form_type":"4"}},{"id":2136915,"issuer":{"id":123059,"kind":"organization","name":"Forma Therapeutics Holdings, Inc.","symbol":"FMTX"},"owners":[{"id":19879,"kind":"person","name":"Bishop John E","position":1,"cik":"0001308911","reported_name":"Bishop John E","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, Chief Technology Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2022-10-14T20:06:49.000Z","date":"2022-10-14","kind":"disposition_to_issuer","acquired":false,"shares":67000,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the \"Merger Agreement\"), dated as of August 31, 2022, by and among Forma Therapeutics Holdings, Inc. (the \"Issuer\"), Novo Nordisk A/S (the \"Parent\"), and NNUS New Dev, Inc., a wholly owned indirect subsidiary of Parent (\"Merger Sub\"), pursuant to which Merger Sub completed a cash tender offer for shares of common stock of the Issuer (each, a \"Share\") and thereafter merged with and into the Issuer (the \"Merger\"), effective as of October 14, 2022 (the \"Effective Time\"). At the Effective Time, each issued and outstanding Share was cancelled and converted into the right to receive $20.00 in cash (the \"Merger Consideration\"), subject to withholding of applicable taxes and without interest."},{"field":"kind","element":"transactionCoding","label":"F3","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each option (whether vested or unvested) that was outstanding and unexercised immediately prior to the Effective Time, was cancelled and converted into the right to receive, for each Share underlying such option, an amount in cash equal to the excess, if any, of the Merger Consideration over the exercise price per share of such option. Each option that was outstanding and unexercised immediately prior to the Effective Time which had a per share exercise price greater than or equal to the Merger Consideration was cancelled with no consideration payable."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each option (whether vested or unvested) that was outstanding and unexercised immediately prior to the Effective Time, was cancelled and converted into the right to receive, for each Share underlying such option, an amount in cash equal to the excess, if any, of the Merger Consideration over the exercise price per share of such option. Each option that was outstanding and unexercised immediately prior to the Effective Time which had a per share exercise price greater than or equal to the Merger Consideration was cancelled with no consideration payable."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each option (whether vested or unvested) that was outstanding and unexercised immediately prior to the Effective Time, was cancelled and converted into the right to receive, for each Share underlying such option, an amount in cash equal to the excess, if any, of the Merger Consideration over the exercise price per share of such option. Each option that was outstanding and unexercised immediately prior to the Effective Time which had a per share exercise price greater than or equal to the Merger Consideration was cancelled with no consideration payable."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each option (whether vested or unvested) that was outstanding and unexercised immediately prior to the Effective Time, was cancelled and converted into the right to receive, for each Share underlying such option, an amount in cash equal to the excess, if any, of the Merger Consideration over the exercise price per share of such option. Each option that was outstanding and unexercised immediately prior to the Effective Time which had a per share exercise price greater than or equal to the Merger Consideration was cancelled with no consideration payable."}],"balance_after":0,"derivative":{"exercise_price":24.26,"underlying":"Common Stock","underlying_shares":67000},"source":{"system":"sec-edgar","filing":"0000899243-22-033652","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1308911/000089924322033652/doc4.xml","form_type":"4"}},{"id":2136914,"issuer":{"id":123059,"kind":"organization","name":"Forma Therapeutics Holdings, Inc.","symbol":"FMTX"},"owners":[{"id":19879,"kind":"person","name":"Bishop John E","position":1,"cik":"0001308911","reported_name":"Bishop John E","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, Chief Technology Officer"}}],"security":"Common Stock","published_at":"2022-10-14T20:06:49.000Z","date":"2022-10-14","kind":"other","acquired":false,"shares":47950,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the \"Merger Agreement\"), dated as of August 31, 2022, by and among Forma Therapeutics Holdings, Inc. (the \"Issuer\"), Novo Nordisk A/S (the \"Parent\"), and NNUS New Dev, Inc., a wholly owned indirect subsidiary of Parent (\"Merger Sub\"), pursuant to which Merger Sub completed a cash tender offer for shares of common stock of the Issuer (each, a \"Share\") and thereafter merged with and into the Issuer (the \"Merger\"), effective as of October 14, 2022 (the \"Effective Time\"). At the Effective Time, each issued and outstanding Share was cancelled and converted into the right to receive $20.00 in cash (the \"Merger Consideration\"), subject to withholding of applicable taxes and without interest."},{"field":"kind","element":"transactionCoding","label":"F2","text":"Consists of restricted stock units (\"RSUs\"), including those RSUs settled into Shares upon vesting. Pursuant to the terms of the Merger Agreement, at the Effective Time, each RSU (whether vested or unvested) that was outstanding immediately prior to the Effective Time, was cancelled and converted into the right to receive, for each Share underlying such RSU, an amount in cash equal to the Merger Consideration, subject to withholding of applicable taxes and without interest."},{"field":"shares","element":"transactionShares","label":"F2","text":"Consists of restricted stock units (\"RSUs\"), including those RSUs settled into Shares upon vesting. Pursuant to the terms of the Merger Agreement, at the Effective Time, each RSU (whether vested or unvested) that was outstanding immediately prior to the Effective Time, was cancelled and converted into the right to receive, for each Share underlying such RSU, an amount in cash equal to the Merger Consideration, subject to withholding of applicable taxes and without interest."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Consists of restricted stock units (\"RSUs\"), including those RSUs settled into Shares upon vesting. Pursuant to the terms of the Merger Agreement, at the Effective Time, each RSU (whether vested or unvested) that was outstanding immediately prior to the Effective Time, was cancelled and converted into the right to receive, for each Share underlying such RSU, an amount in cash equal to the Merger Consideration, subject to withholding of applicable taxes and without interest."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0000899243-22-033652","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1308911/000089924322033652/doc4.xml","form_type":"4"}},{"id":2359905,"issuer":{"id":123059,"kind":"organization","name":"Forma Therapeutics Holdings, Inc.","symbol":"FMTX"},"owners":[{"id":19879,"kind":"person","name":"Bishop John E","position":1,"cik":"0001308911","reported_name":"Bishop John E","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, Chief Technology Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2022-03-02T22:14:30.000Z","date":"2022-02-28","kind":"grant","acquired":true,"shares":38930,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"25% of the shares subject to the stock option shall vest on February 28, 2023, and the remainder of the shares vest in equal monthly installments for a period of 36 months thereafter."}],"balance_after":38930,"derivative":{"exercise_price":9.86,"expiration_date":"2032-02-27","underlying":"Common Stock","underlying_shares":38930},"source":{"system":"sec-edgar","filing":"0000899243-22-008643","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1308911/000089924322008643/doc4.xml","form_type":"4"}},{"id":2359904,"issuer":{"id":123059,"kind":"organization","name":"Forma Therapeutics Holdings, Inc.","symbol":"FMTX"},"owners":[{"id":19879,"kind":"person","name":"Bishop John E","position":1,"cik":"0001308911","reported_name":"Bishop John E","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, Chief Technology Officer"}}],"security":"Common Stock","published_at":"2022-03-02T22:14:30.000Z","date":"2022-02-28","kind":"grant","acquired":true,"shares":25950,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"These shares represented restricted stock units and will be settled into common stock upon vesting. Each restricted stock unit would be converted into one share of FMTX common stock."}],"balance_after":47950,"source":{"system":"sec-edgar","filing":"0000899243-22-008643","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1308911/000089924322008643/doc4.xml","form_type":"4"}},{"id":2667916,"issuer":{"id":123059,"kind":"organization","name":"Forma Therapeutics Holdings, Inc.","symbol":"FMTX"},"owners":[{"id":19879,"kind":"person","name":"Bishop John E","position":1,"cik":"0001308911","reported_name":"Bishop John E","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Technology Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2021-06-15T20:15:00.000Z","date":"2021-06-14","kind":"grant","acquired":true,"shares":67000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"25% of the shares subject to the stock option shall vest on June 14, 2022, and the remainder of the shares shall vest in equal monthly installments for a period of 36 months thereafter, subject to continued service with the Issuer."}],"balance_after":67000,"derivative":{"exercise_price":24.26,"expiration_date":"2031-06-13","underlying":"Common Stock","underlying_shares":67000},"source":{"system":"sec-edgar","filing":"0000899243-21-023855","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1308911/000089924321023855/doc4.xml","form_type":"4"}},{"id":2667915,"issuer":{"id":123059,"kind":"organization","name":"Forma Therapeutics Holdings, Inc.","symbol":"FMTX"},"owners":[{"id":19879,"kind":"person","name":"Bishop John E","position":1,"cik":"0001308911","reported_name":"Bishop John E","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Technology Officer"}}],"security":"Common Stock","published_at":"2021-06-15T20:15:00.000Z","date":"2021-06-14","kind":"grant","acquired":true,"shares":22000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"These shares represented restricted stock units and will be settled into common stock upon vesting. Each restricted stock unit would be converted into one share of FMTX common stock."}],"balance_after":22000,"source":{"system":"sec-edgar","filing":"0000899243-21-023855","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1308911/000089924321023855/doc4.xml","form_type":"4"}}]}